慢性荨麻疹患者应用枸地氯雷他定的效果及其血清相关因子水平表达的影响

Curative Effect of Desloratadine Citrate Disodium in Patients with Chronic Urticaria and Its Influence on Serum levels

目的观察慢性荨麻疹(Chronic urticaria,CU)患者临床应用枸地氯雷他定的效果及其血清白细胞介素-4(interleukin-4,IL-4)、白细胞介素-18(interleukin-18,IL-18)、白细胞介素-23(interleukin-23,IL-23)和白细胞介素-33(interleukin-33,IL-33)水平表达的影响。方法选取2015年3月—2016年9月甘肃省武威肿瘤医院收治的CU患者116例作为研究对象,随机分为对照组与研究组,每组各58例。对照组给予氯雷他定片治疗,研究组给予枸地氯雷他定片治疗,两组均持续治疗4周。统计两组治疗前后荨麻疹活动性评分(Urticaria activity score,UAS)及皮肤病生活质量指数(Dermatology Life Quality Index,DLQI)评分,比较两组治疗后临床疗效及治疗中产生的不良反应,检测治疗前后两组血清IL-4、IL-18、IL-23和IL-33水平。结果治疗后两组UAS、DLQI评分和血清指标均得到明显的降低,且研究组结果优于对照组(P<0.05);治疗后研究组、对照组总有效率分别为84.48%、63.79%,差异显著(P<0.05),两组患者在不良反应发生率方面无明显差异(P>0.05);结论 CU患者临床应用枸地氯雷他定治疗效果显著,可改善其血清IL-4、IL-18、IL-23和IL-33表达水平。

OBJECTIVE To investigate the curative effect of desloratadine citrate disodium in patients with chronic urticaria（CU） and its influence on serum interleukin-4（IL-4）,interleukin-18（IL-18）,interleukin-23（IL-23）and interleukin-33（IL-33） levels.METHODS 116 CU patients in target hospital from March 2015 to September 2016 were randomly divided into two groups： control group and study group,each with 58 cases.The control group was given loratadine treatment,while the study group was given desloratadine citrate Disodium treatment,and the 2 groups treatments were continued for 4 weeks.The urticaria activity score（UAS） and Dermatology Life Quality Index（DLQI） score of the 2 groups before and after treatments were counted,curative effects after treatment and adverse reactions during treatment of the 2 groups were compared,and serum IL-4,IL-18,IL-23 and IL-33 levels of the 2 groups before and after treatments were detected.RESULTS After treatment,the UAS and DLQI scores of the 2 groups were significantly lower than before（P〈0.05）,and the study group were significantly lower than that of the control group（P〈0.05）.After treatment,the total effective rate of the study was 84.48%,significantly higher than that of the control group known as 63.79%（P〈0.05）,and there was no significant difference in the incidence of adverse reactions between the 2 groups（P〉0.05）; After treatment,serum IL-4,IL- 18,IL-23 and IL-33 levels of the 2 groups were significantly lower than before（P〈0.05）,and the study group was significantly lower than that of the control group（P〈0.05）.CONCLUSION Desloratadine citrate disodium for patients with CU could significantly increase curative effect,improve their serum IL-4,IL-18,IL-23 and IL-33 levels.